Aptose Biosciences Inc.
APTOF
$1.71
$0.031.91%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.38M | 12.07M | 11.63M | 10.94M | 11.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.72M | 19.48M | 21.53M | 21.96M | 26.26M |
| Operating Income | -24.72M | -19.48M | -21.53M | -21.96M | -26.26M |
| Income Before Tax | -25.47M | -19.29M | -21.12M | -21.33M | -25.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.47 | -19.29 | -21.12 | -21.33 | -25.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.47M | -19.29M | -21.12M | -21.33M | -25.43M |
| EBIT | -24.72M | -19.48M | -21.53M | -21.96M | -26.26M |
| EBITDA | -24.70M | -19.46M | -21.52M | -21.94M | -26.23M |
| EPS Basic | -10.41 | -8.71 | -18.03 | -28.26 | -47.68 |
| Normalized Basic EPS | -6.51 | -5.44 | -11.27 | -17.66 | -29.80 |
| EPS Diluted | -10.41 | -8.71 | -18.03 | -28.26 | -47.68 |
| Normalized Diluted EPS | -6.51 | -5.44 | -11.27 | -17.66 | -29.80 |
| Average Basic Shares Outstanding | 9.78M | 8.42M | 6.48M | 4.48M | 2.80M |
| Average Diluted Shares Outstanding | 9.78M | 8.42M | 6.48M | 4.48M | 2.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |